Phase 4
N=60
Spinal Anaesthesia With Levobupivacaine 0.5% and Ropivacaine 0.75% for Lower Limb Orthopaedic Surgery
Lower Limb Surgery
Bottom Line
View on ClinicalTrials.gov: NCT02201784 ↗Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Jan 2015
Primary outcome: Primary: Duration of Analgesia — 309.83; 249.50 minutes
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Levobupivacaine (Drug); Ropivacaine (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Aligarh Muslim University
- Primary completion
- Jan 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Duration of Analgesia |
309.83; 249.50 | — |
| SECONDARY Onset of Sensory Block at T10 |
13.50; 7.33 | — |
| SECONDARY Median Maximum Level of Sensory Blockade |
— | — |
| SECONDARY Time to Maximum Cephalic Spread of Sensory Block |
20.33; 13.17 | — |
| SECONDARY Onset of Motor Block to Bromage3 |
12.17; 7.83 | — |
| SECONDARY Duration of Motor Block |
290.50; 222.50 | — |
Summary
The purpose of this study is to compare the effects of two intrathecally administered drugs:0.5% levobupivacaine and0.75%Ropivacaine in spinal anesthesia
Eligibility Criteria
Inclusion Criteria
- American Society of Anesthesiologists (ASA) class I & II patients of either sex
- Age between 18-60 years
Exclusion Criteria
- Patient's refusal.
- Patients who have contraindications to spinal anaesthesia / Local anaesthetic drugs.
- Patients having h/o diabetes, neurological and musculoskeletal diseases.
Data sourced from ClinicalTrials.gov (NCT02201784). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.